Gilead Sciences, Inc.

The US Food and Drug Administration has placed a clinical hold on Gilead’s HIV treatment trials of GS-1720 and GS-4182 due to low levels of CD4+T-cell (CD4) and absolute lymphocyte counts in a subset

Gilead Sciences’ Kite division is stepping into cell therapy for solid tumors with encouraging early efficacy data in one of the toughest of all cancers to treat, having presented Phase I results for

Gilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative r

Kymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa